What is the 13F Pro Quality Score for AMRN?

13F Pro ranks AMARIN CORP PLC\UK (AMRN) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AMRN's current score at https://13fpro.ai/research/AMRN (free sign-up required for the full ranking).

Where does 13F Pro source AMRN data?

All AMARIN CORP PLC\UK fundamentals and ownership data come directly from SEC EDGAR. AMARIN CORP PLC\UK files with the SEC under CIK 897448. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AMRN in?

AMARIN CORP PLC\UK (AMRN) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AMRN research updated on 13F Pro?

AMRN's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AMARIN CORP PLC\UK(AMRN)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 897448 AMRN stock profile & AI dashboard →

13F Pro Quality Score

22.6/100

Rank #2,635 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

8.8/100

Profitability

15.6/100

Balance Sheet

20.7/100

Earnings Quality

30.0/100

Free Cash Flow

31.1/100

Institutional Flow

71.0/100

Revenue Scale

25.0/100

Dilution Risk

22.2/100

AMRN Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AMARIN CORP PLC\UK (AMRN), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AMRN at 22.6/100 on a 32-signal composite quality model, placing it at rank #2,635 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue growth (8.8) and profitability (15.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), AMARIN CORP PLC\UK reports quarterly revenue of $45.1M, net income of $-10.5M, an operating margin of -25.1%. Top institutional holders of AMRN by reported 13-F value include Sarissa Capital Management, Kynam Capital Management,, MILLENNIUM MANAGEMENT, based on the most recent SEC filings. AMRN trades on the Nasdaq exchange and files with the SEC under CIK 897448. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AMRN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AMARIN CORP PLC\UK directly from SEC EDGAR. AMARIN CORP PLC\UK's 13F Pro composite quality score has ranged between 15 and 52 since 2021, currently 22.6 — a declining long-term trajectory across 30 quarterly and live scoring snapshots.

✦

Fun facts about AMARIN CORP PLCUK

Quirks, history, and lore behind AMRN — the kind of stuff that makes a stock memorable.

1
The Basics
A specialty pharmaceutical company · small-cap · incorporated in Ireland · with operations focused on a single therapeutic area: cardiovascular disease.
2
The Numbers
Revenue is modest by pharma standards — largely dependent on one product — and the company has spent years navigating the difference between blockbuster hopes and generic competition reality.
3
The History
Founded in the 1990s, it spent well over a decade and hundreds of millions of dollars winning FDA approval for a drug derived from highly purified fish oil.
4
The Secret
Its lone flagship drug, approved by the FDA in 2012, was shown in a landmark trial to reduce cardiovascular events in patients with persistently high triglycerides — a genuinely novel result that set off a legal firestorm over patents.
5
The Lore
When generic rivals won the right to copy its drug after a patent battle, the stock cratered catastrophically — a cautionary tale of a company that bet everything on one pill made from omega-3 fatty acids.
6
The Giveaway
Its drug Vascepa — an ultra-pure icosapentaenoic acid capsule — was the fish-oil pill that almost conquered cardiology, until the generics swam upstream.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$45.1M

Net Income

Q1 2026

$-10.5M

Free Cash Flow

Q1 2026

$6.4M

Operating Margin

Q1 2026

-25.1%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-6.5% YoY

$213.6MFY 2025

FY21 $583.2MFY22 $369.2MFY24 $228.6MFY25 $213.6M

Net Income

+52.8% YoY

$-38.8MFY 2025

FY21 $7.7MFY22 $-105.8MFY24 $-82.2MFY25 $-38.8M

Operating Income

+45.3% YoY

$-50.2MFY 2025

FY21 $10.5MFY22 $-105.9MFY24 $-91.8MFY25 $-50.2M

EPS (Diluted)

+55.0% YoY

$-0.09FY 2025

FY21 $0.02FY22 $-0.26FY24 $-0.20FY25 $-0.09

Total Assets

-2.1% YoY

$670.8MFY 2025

FY21 $1.07BFY22 $886.2MFY24 $685.3MFY25 $670.8M

Total Debt

—FY 2025

FY21 $0.00FY22 —FY24 —FY25 —

Op. Cash Flow

+121.7% YoY

$6.7MFY 2025

FY21 $-66.5MFY22 $-180.1MFY24 $-31.0MFY25 $6.7M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$213.6M -6.5%	$228.6M -38.1%	$369.2M -36.7%	$583.2M -5.0%	$614.1M +42.9%	$429.8M
Net Income	$-38.8M +52.8%	$-82.2M +22.3%	$-105.8M -1474.0%	$7.7M +142.8%	$-18.0M +20.5%	$-22.6M
Operating Income	$-50.2M +45.3%	$-91.8M +13.3%	$-105.9M -1108.1%	$10.5M +153.4%	$-19.7M +19.0%	$-24.3M
EPS (Diluted)	$-0.09 +55.0%	$-0.20 +23.1%	$-0.26 -1400.0%	$0.02 +140.0%	$-0.05 +28.6%	$-0.07
Total Assets	$670.8M -2.1%	$685.3M -22.7%	$886.2M -17.0%	$1.07B +10.6%	$966.0M +9.5%	$882.2M
Total Debt	—	—	—	$0.00	$0.00 -100.0%	$99.8M
Operating Cash Flow	$6.7M +121.7%	$-31.0M +82.8%	$-180.1M -170.7%	$-66.5M -206.0%	$-21.7M -132.2%	$-9.4M

Get alerted when AMRN's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AMARIN CORP PLC\UK including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AMRN

Sarissa Capital Management LP
$24.2M1,673,395 sh
Kynam Capital Management, LP
$6.8M472,382 sh
MILLENNIUM MANAGEMENT LLC
$4.3M300,536 sh
MORGAN STANLEY
$4.2M293,172 sh
Point72 Asset Management, L.P.
$3.5M240,761 sh
Waterfront Wealth Inc.
$2.9M203,338 sh
Eversept Partners, LP
$2.1M147,715 sh
TWO SIGMA INVESTMENTS, LP
$1.6M107,542 sh
CITADEL ADVISORS LLC
$1.2M80,575 sh
BNP PARIBAS FINANCIAL MARKETS
$1.1M75,503 sh

Fund	Value	Shares
Sarissa Capital Management LP	$24.2M	1,673,395
Kynam Capital Management, LP	$6.8M	472,382
MILLENNIUM MANAGEMENT LLC	$4.3M	300,536
MORGAN STANLEY	$4.2M	293,172
Point72 Asset Management, L.P.	$3.5M	240,761
Waterfront Wealth Inc.	$2.9M	203,338
Eversept Partners, LP	$2.1M	147,715
TWO SIGMA INVESTMENTS, LP	$1.6M	107,542
CITADEL ADVISORS LLC	$1.2M	80,575
BNP PARIBAS FINANCIAL MARKETS	$1.1M	75,503

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AMRN on your watchlist

Track score changes the day AMARIN CORP PLC\UK files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AMRN a good stock to buy?

13F Pro's AI-powered analysis of AMARIN CORP PLC\UK (AMRN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AMRN are available on the AMRN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AMRN?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AMRN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AMARIN CORP PLC\UK's investment landscape.